In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years)

In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years) is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - In patients with T2DM and CV disease, empagliflozin reduces CV and all-cause mortality (NNT = 38 over 3.3 years) ID - 428480 ED - Barry,Henry, ED - Ebell,Mark H, ED - Shaughnessy,Allen F, ED - Slawson,David C, BT - EE+ POEM Archive UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/428480/all/In_patients_with_T2DM_and_CV_disease__empagliflozin_reduces_CV_and_all_cause_mortality__NNT_=_38_over_3_3_years_ PB - John Wiley & Sons DB - Evidence Central DP - Unbound Medicine ER -